Antimicrobial Susceptibility Profiles and Prevalence of ESBLS among Escherichia coli Isolates Recovered from Clinical Specimens in Different Services

Abstract

Objective: A retrospective analysis of the widely used antibiotics all susceptibility testing results from Escherichia coli cultured from clinical specimens private hospital from (January 2016 to November 2018) was performed. Methods: The VITEK 2 Compact automated microbiology system is designed for automated rapid antimicrobial susceptibility testing and identification of clinically relevant bacteria. Minimum inhibitory concentration (MIC) results previously obtained in recent clinical isolates with well-defined in isolates with well-characterized resistance mechanisms with the microdilution method were re-interpreted for the susceptible, intermediate and resistant categories using the 2018 EUCAST breakpoints. Clinical samples are most commonly isolated from blood, sputum and urine samples. Results: Escherichia coli isolates were highly resistant to ampicillin, cefuroxime and cefixime 79,16%, 60,41% and 58,33% respectively. Resistance rate of ceftriaxon was showed in 52,08%. When we compared to resistance of trimethoprim/sulfamethoxazole, Escherichia coli isolates showed 51,04% resistance rate. When it comes to the most sensitive antibiotics, sensitivity rate of fosfomycin, nitrofurantoin, ertapenem, imipenem, meropenem, gentamicin, and amikacin were 89,58%; 91,66%; 93,75%; 93,75%; 94,79%; 83,33%; 84,37% respectively. Conclusion: Considering the antibiogram, fosfomycin, nitrofurantoin, ertapenem, imipenem, meropenem, gentamicin and amikacin should be preferred drugs for E. coli infection isolated from clinical samples.